WO1997023230A1 - Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase - Google Patents
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase Download PDFInfo
- Publication number
- WO1997023230A1 WO1997023230A1 PCT/US1996/020649 US9620649W WO9723230A1 WO 1997023230 A1 WO1997023230 A1 WO 1997023230A1 US 9620649 W US9620649 W US 9620649W WO 9723230 A1 WO9723230 A1 WO 9723230A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- dideoxycytidine
- deaminase
- dideoxy
- azidocytidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9523869A JPH11513992A (en) | 1995-12-22 | 1996-12-23 | Agents and methods for treating diseases involving overexpression of cytidine deaminase or deoxycytidine deaminase |
KR1019980704809A KR19990076695A (en) | 1995-12-22 | 1996-12-23 | Active Agents and Methods for Treating Diseases Associated with Overexpression of Cytidine Deaminase or Deoxycytidine Deaminase |
EP96945043A EP0876149A4 (en) | 1995-12-22 | 1996-12-23 | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase |
AU13501/97A AU728377C (en) | 1995-12-22 | 1996-12-23 | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57718595A | 1995-12-22 | 1995-12-22 | |
US08/577,185 | 1995-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997023230A1 true WO1997023230A1 (en) | 1997-07-03 |
Family
ID=24307627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/020649 WO1997023230A1 (en) | 1995-12-22 | 1996-12-23 | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase |
Country Status (8)
Country | Link |
---|---|
US (1) | US6136791A (en) |
EP (1) | EP0876149A4 (en) |
JP (1) | JPH11513992A (en) |
KR (1) | KR19990076695A (en) |
AU (1) | AU728377C (en) |
CA (1) | CA2241255A1 (en) |
RU (1) | RU98113785A (en) |
WO (1) | WO1997023230A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US9381207B2 (en) | 2011-08-30 | 2016-07-05 | Astex Pharmaceuticals, Inc. | Drug formulations |
WO2016195353A1 (en) * | 2015-06-01 | 2016-12-08 | Kainos Medicine, Inc. | A use of 1'-cyano-cytarabine for cancer treatment |
US9605197B2 (en) * | 2012-02-29 | 2017-03-28 | Global Green Products Llc | System and method for inhibiting scale formation in oil wells |
US10485764B2 (en) | 2015-07-02 | 2019-11-26 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
US10519190B2 (en) | 2017-08-03 | 2019-12-31 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
US11963973B2 (en) | 2019-02-01 | 2024-04-23 | Hemispherian As | Deoxy-cytidine or uridine derivatives for use in cancer therapies |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432924B1 (en) * | 1993-12-26 | 2002-08-13 | East Carolina University | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase |
US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
ES2538486T3 (en) * | 2002-09-12 | 2015-06-22 | International Institute Of Cancer Immunology, Inc. | Preparation of antigenic peptides against cancer |
US20040162263A1 (en) * | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
US20060063735A1 (en) * | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
NZ718607A (en) | 2013-10-29 | 2019-10-25 | Otsuka Pharma Co Ltd | Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines |
WO2017158396A1 (en) * | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
US11209421B2 (en) * | 2016-03-31 | 2021-12-28 | Centre National De La Recherche Scientifique | Cytidine deaminase expression level in cancer as a new therapeutic target |
US11938143B2 (en) | 2021-10-19 | 2024-03-26 | Akirabio, Inc. | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3891623A (en) * | 1971-05-04 | 1975-06-24 | Schering Ag | Process for preparing cytidines |
US5079235A (en) * | 1986-12-15 | 1992-01-07 | Burroughs Wellcome Co. | Antiviral compounds |
US5215971A (en) * | 1986-12-19 | 1993-06-01 | Medivir Ab | Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides |
US5576429A (en) * | 1988-06-10 | 1996-11-19 | Medivir Ab | 5-substituted pyrimidine nucleosides and nucleotides |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501744A (en) * | 1980-09-16 | 1985-02-26 | Ens Bio Logicals Inc. | Substituted-aza-cytosine compounds and anti-viral uses thereof |
US5084445A (en) * | 1986-05-01 | 1992-01-28 | University Of Georgia Research Foundation, Inc. | 3'-azido-2',3'-dideoxy-5-methylcytidine |
US4788181A (en) * | 1986-09-29 | 1988-11-29 | The United States Of America As Represented By The Department Of Health And Human Services | 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity |
US5652099A (en) * | 1992-02-12 | 1997-07-29 | Conrad; Michael J. | Probes comprising fluorescent nucleosides and uses thereof |
-
1996
- 1996-12-23 CA CA002241255A patent/CA2241255A1/en not_active Abandoned
- 1996-12-23 WO PCT/US1996/020649 patent/WO1997023230A1/en not_active Application Discontinuation
- 1996-12-23 EP EP96945043A patent/EP0876149A4/en not_active Withdrawn
- 1996-12-23 AU AU13501/97A patent/AU728377C/en not_active Ceased
- 1996-12-23 US US08/772,455 patent/US6136791A/en not_active Expired - Fee Related
- 1996-12-23 KR KR1019980704809A patent/KR19990076695A/en not_active Application Discontinuation
- 1996-12-23 RU RU98113785/14A patent/RU98113785A/en not_active Application Discontinuation
- 1996-12-23 JP JP9523869A patent/JPH11513992A/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3891623A (en) * | 1971-05-04 | 1975-06-24 | Schering Ag | Process for preparing cytidines |
US5079235A (en) * | 1986-12-15 | 1992-01-07 | Burroughs Wellcome Co. | Antiviral compounds |
US5215971A (en) * | 1986-12-19 | 1993-06-01 | Medivir Ab | Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides |
US5576429A (en) * | 1988-06-10 | 1996-11-19 | Medivir Ab | 5-substituted pyrimidine nucleosides and nucleotides |
Non-Patent Citations (1)
Title |
---|
See also references of EP0876149A4 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US10456415B2 (en) | 2005-09-29 | 2019-10-29 | Astex Pharmaceuticals, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US8461123B2 (en) | 2005-09-29 | 2013-06-11 | Astex Pharmaceuticals, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US9358248B2 (en) | 2005-09-29 | 2016-06-07 | Astex Pharmaceuticals, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US10933079B2 (en) | 2005-09-29 | 2021-03-02 | Astex Pharmaceuticals, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US9480698B2 (en) | 2005-09-29 | 2016-11-01 | Astex Pharmaceuticals, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US10517886B2 (en) | 2011-08-30 | 2019-12-31 | Astex Pharmaceuticals, Inc. | Drug formulations |
US9913856B2 (en) | 2011-08-30 | 2018-03-13 | Astex Pharmaceuticals, Inc. | Drug formulations |
US9381207B2 (en) | 2011-08-30 | 2016-07-05 | Astex Pharmaceuticals, Inc. | Drug formulations |
US9914869B2 (en) | 2012-02-29 | 2018-03-13 | Global Green Products Llc | System and method for inhibiting scale formation in oil wells |
US9605197B2 (en) * | 2012-02-29 | 2017-03-28 | Global Green Products Llc | System and method for inhibiting scale formation in oil wells |
WO2016195353A1 (en) * | 2015-06-01 | 2016-12-08 | Kainos Medicine, Inc. | A use of 1'-cyano-cytarabine for cancer treatment |
US10485764B2 (en) | 2015-07-02 | 2019-11-26 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
US10519190B2 (en) | 2017-08-03 | 2019-12-31 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
US11963973B2 (en) | 2019-02-01 | 2024-04-23 | Hemispherian As | Deoxy-cytidine or uridine derivatives for use in cancer therapies |
Also Published As
Publication number | Publication date |
---|---|
AU728377B2 (en) | 2001-01-11 |
AU728377C (en) | 2003-10-30 |
AU1350197A (en) | 1997-07-17 |
EP0876149A1 (en) | 1998-11-11 |
JPH11513992A (en) | 1999-11-30 |
CA2241255A1 (en) | 1997-07-03 |
US6136791A (en) | 2000-10-24 |
RU98113785A (en) | 2000-06-10 |
KR19990076695A (en) | 1999-10-15 |
EP0876149A4 (en) | 2001-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU728377C (en) | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase | |
EP1491201B1 (en) | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | |
KR100256144B1 (en) | Composition of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides | |
EA005890B1 (en) | Methods for treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides | |
NZ583824A (en) | Azacytidine analogues and uses thereof | |
SK281231B6 (en) | Monoester compound, pharmaceutical composition it containing, and use of this compound | |
US6432924B1 (en) | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase | |
WO1994026761A1 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
EP2416781B1 (en) | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer | |
EP2335706A1 (en) | Preparation of thioarabinofuranosyl compounds and use thereof | |
US20220145304A1 (en) | Modified micrornas and their use in the treatment of cancer | |
US5166140A (en) | Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy | |
US8609631B2 (en) | Compositions and methods for treating cancer | |
AU639973B2 (en) | Circumvention of human tumor drug resistance | |
JP2012522840A (en) | (2'-Deoxy-ribofuranosyl) -1,3,4,7-tetrahydro- (1,3) diazepin-2-one derivatives for treating cancer | |
MXPA98005083A (en) | Method of treatment of disorders characterizopopor the over-expression of citidina deaminasa or deoxicitidina deamin | |
US8586561B2 (en) | Anti-tumor agent comprising cytidine derivative and carboplatin | |
AU2002300586B2 (en) | A method for treating solid tumors | |
WO1995027493A1 (en) | Pyrimidine deoxyribonucleoside potentiation of combination therapy based on 5-fluorouracil and interferon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96199232.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2241255 Country of ref document: CA Ref document number: 2241255 Country of ref document: CA Kind code of ref document: A Ref document number: 1997 523869 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980704809 Country of ref document: KR Ref document number: PA/a/1998/005083 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996945043 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref document number: 97523869 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1996945043 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980704809 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996945043 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980704809 Country of ref document: KR |